Insulin resistance by TNF-α is associated with mitochondrial dysfunction in 3T3-L1 adipocytes and is ameliorated by punicic acid, a PPARγ agonist

Molecular and Cellular Endocrinology

Volumn 413, Issue , 2015, Pages 120-128

  Anusree, S S ^a   Nisha, V M ^a   Priyanka, A ^a   Raghu, K G ^a  

^a REGIONAL RESEARCH LABORATORY CSIR   (India)

Author keywords

Insulin resistance; Mitochondrial biogenesis; Mitochondrial dynamics; PPAR ; TNF ; Transmembrane potential

Indexed keywords

ACONITATE HYDRATASE; ADENOSINE TRIPHOSPHATE; BETA ACTIN; MESSENGER RNA; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PUNICIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANSCRIPTION FACTOR NRF1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; LINOLENIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BIOGENESIS; CONTROLLED STUDY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY TRANSFER; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE DOSAGE; GENE EXPRESSION; GLUCOSE TRANSPORT; INSULIN RESISTANCE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; 3T3 CELL LINE; AGONISTS; ANIMAL; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; MITOCHONDRION; PATHOLOGY;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; ENERGY METABOLISM; INSULIN RESISTANCE; LINOLENIC ACIDS; MICE; MITOCHONDRIA; PPAR GAMMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84938285285     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.06.018     Document Type: Article

References (55)

1. Ahmadian M., Suh J.M., Hah N., Liddle C., Atkins A.R., Downes M., et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat. Med. 2013, 19:557-566.
2. Anusree S.S., Priyanka A., Nisha V.M., Das A.A., Raghu K.G. An in vitro study reveals the nutraceutical potential of punicic acid relevant to diabetes via enhanced GLUT4 expression and adiponectin secretion. Food Funct. 2014, 10:2590-2601.
3. Archer S.L. Mitochondrial dynamics-mitochondrial fission and fusion in human diseases. N. Engl. J. Med. 2013, 369:2236-2251.
4. Barbara B.K., Jeffrey S.F. Obesity and insulin resistance. J. Clin. Invest. 2000, 106:473-481.
5. Bassaganya-Riera J., Guri A.J., Hontecillas R. Treatment of obesity-related complications with novel classes of naturally occurring PPAR agonists. J. Obes. 2011, 10.1155/2011/897894.
6. Belenguer P., Pellegrini L. The dynamin GTPase OPA1: more than mitochondria?. Biochim. Biophys. Acta 2013, 1833:176-183.
7. Bogacka I., Xie H., Bray G.A., Smith S.R. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005, 54:1392-1399.
8. Boussetta T., Raad H., Lettéron P., Gougerot-Pocidalo M.A., Marie J.C., Driss F., et al. Punicic acid a conjugated linolenic acid inhibits TNFalpha induced neutrophil hyperactivation and protects from experimental colon inflammation in rats. PLoS One 2009, 2009. 10.1371/journal.pone.0006458.
9. Brand M.D., Nicholls D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011, 435:297-312.
10. Brooks C., Wei Q., Cho S.G., Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J. Clin. Invest. 2009, 119:1275-1285.
11. Cawthorn W.P., Sethi J.K. TNF-alpha and adipocyte biology. FEBS Lett. 2008, 582:117-131.
12. Chan D.C. Mitochondrial fusion and fission in mammals. Annu Rev. Cell. Dev. Biol. 2006, 22:79-99.
13. Chen H., Chomyn A., Chan D.C. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J. Biol. Chem. 2005, 280:26185-26192.
14. Chen X.H., Zhao Y.P., Xue M., Ji C.B., et al. TNF-alpha induces mitochondrial dysfunction in 3T3-L1 adipocytes. Mol. Cell. Endocrinol. 2010, 2010(328):63-69.
15. Davi G., Santilli F., Patrono C. Nutraceuticals in diabetes and metabolic syndrome. Cardiovasc. Ther. 2010, 28:216-226.
16. de Pauw A., Tejerina S., Raes M., Keijer J., Arnould T. Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations. Am. J. Pathol. 2009, 175:927-939.
17. de Melo I.L., de Carvalho M.L., Mancini-Filho J. Pomegranate seed oil (Punica granatum L.): a source of punicic acid (conjugated α-linolenic acid). J. Hum. Nutr. Food Sci. 2014, 1024:2-11.
18. Graf B.L., Raskin I., Cefalu W.T., Ribnicky D.M. Plant-derived therapeutics for the treatment of metabolic syndrome. Curr. Opin. Investig. Drugs 2010, 10:1107-1115.
19. Hafizi M., Bakar A. Mitochondrial dysfunction enhances lipolysis and intracellular lipid accumulation in 3T3-L1 adipocytes. Int. J. Pharm. Med. Biol. Sci. 2015, 4:65-69.
20. Hahn W.S., Kuzmicic J., Burrill J.S., Donoghue M.A., Foncea R., Jensen M.D., et al. Proinflammatory cytokines differentially regulate adipocyte mitochondrial metabolism, oxidative stress and dynamics. Am. J. Physiol. Endocrinol. Metab. 2014, 10.1152/ajpendo.00422.2013.
21. Hao J., Shen W., Yu G., Jia H., Li X., Feng Z., et al. Hydroxytyrosol promotes mitochondrial biogenesis and mitochondrial function in 3T3-L1 adipocytes. J. Nutr. Biochem. 2010, 21:634-644.
22. Hoehn K.L., Salmon A.B., Hohnen-Behrens C., Turner N., Hoy A.J., Maghzal G.J., et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc. Natl. Acad. Sci. 2009, 106:17787-17792.
23. Hondares E., Mora O., Yubero P., Rodriguez de la Concepción M., Iglesias R., Giralt M., et al. Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation. Endocrinology 2006, 147:2829-2838.
24. Hontecillas R., O'Shea M., Einerhand A., Diguardo M., Bassaganya-Riera J. Activation of PPAR alpha and gamma by punicic acid ameliorates glucose tolerance and suppresses obesity related inflammation. J. Am. Coll. Nutr. 2009, 28:184-195.
25. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271:665-668.
26. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440:944-948.
27. Jeon M.J., Leem J., Ko M.S., Jang J.E., Park H.S., Kim H.S. Mitochondrial dysfunction and activation of iNOS are responsible for the palmitate induced decrease in adiponectin synthesis in 3T3L1 adipocytes. Exp. Mol. Med. 2012, 44:562-570.
28. Jheng H.F., Tsai P.J., Guo S.M., Kuo L.H., Chang C.S., Su I.J., et al. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Mol. Cell. Biol. 2012, 32:309-319.
29. Jing L., He M.T., Chang Y., Mehta S.L., He Q.P., Zhang J.Z., et al. Coenzyme Q10 protects astrocytes from ROSinduced damage through inhibition of mitochondria mediated cell death pathway. Int. J. Biol. Sci. 2015, 11:59-66.
30. Joseph A.M., Joanisse D.R., Baillot R.G., Hood D.A. Mitochondrial dysregulation in the pathogenesis of diabetes: potential for mitochondrial biogenesis-mediated interventions. Exp. Diabetes Res. 2012, 10.1155/2012/642038.
31. Kavishankar G.B., Lakshmidevi N., Mahadeva Murthy S., Prakash H.S., Niranjana S.R. Diabetes and medicinal plants - a review. Int. J. Pharm. Biomed. Sci. 2013, 3:65-80.
32. Kim J.A., Wei Y., Sowers J.R. Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 2008, 102:401-414.
33. Kusminski C.M., Scherer P.E. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol. Metab. 2012, 23:435-443.
34. Landreth G., Jiang Q., Mandrekar S., Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008, 5:481-489.
35. Larsen T.M., Toubro S., Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fates commensurate with long-term efficact?. Int. J. Obes. Relat. Metab. Disord. 2003, 27:147-161.
36. Lebovitz H.E., Banerji M.A. Treatment of insulin resistance in diabetes mellitus. Eur. J. Pharmacol. 2004, 490:135-146.
37. Liu J., Shen W., Zhao B., Wang Y., Wertz K., Weber P., et al. Targeting mitochondrial biogenesis for preventing ad treating insulin resistance in diabetes and obesity: Hope from natural mitochondrial nutrients. Adv. Drug Deliv. Rev. 2009, 61:1343-1352.
38. Miglio G., Rosa A.C., Rattazzi L., Collino M., Lombardi G., Fantozzi R., et al. PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem. Int. 2009, 55:496-504.
39. Morino K., Petersen K.F., Shulman G.I. Molecular mechanism of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006, 55:S9-S15.
40. Ong S.B., Subrayan S., Lim S.Y., Yellon D.M., Davidson S.M., Hausenloy D.J. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 2010, 121:2012-2022.
41. Prakash Y.G., Sumit K., Neyanila S.K., Gopal V. Antioxidant and tyrosinase inhibitory activity of aqueous extract and oil of seeds of Punica granatum L. (Punicaceae). Int. J. Sci. Nat. 2013, 4:508-511.
42. Ramaa C.S., Shirode A.R., Mundada A.S., Kadam V.J. Nutraceuticals - an emerging era in the treatment and prevention of cardiovascular diseases. Curr. Pharm. Biotechnol. 2006, 7:15-23.
43. Relling D.P., Esberg L.B., Fang C.X., Johnson W.T., Murphy E.J., Carlson E.C., et al. High-fat diet induced juvenile obesity leads to cardiomyocyte dysfunction and up regulation of Foxo3a transcription factor independent of lipotoxicity and apoptosis. J. Hypertens. 2006, 24:549-561.
44. Rong J.X., Qiu Y., Hansen M.K., Zhu L., Zhang V., Xie M. Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone. Diabetes 2007, 56:1751-1760.
45. Samavati L., Lee I., Mathes I., Lottspeich F., Hüttemann M. Tumor necrosis factor alpha inhibits oxidative phosphorylation through tyrosine phosphoryoation at subunit I of cytochrome c oxidase. J. Biol. Chem. 2008, 283:21134-31144.
46. Shibasaki M., Takahashi K., Itou T., Bujo H., Saito Y. A PPAR agonist improves TNF- alpha-induced insulin resistance of adipose tissue in mice. Biochem. Biophys. Res. Commun. 2003, 309:419-424.
47. Sivitz W.I., Yorek M.A. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid. Redox Signal 2010, 12:537-577.
48. Song Z., Ghochani M., McCaffery J.M., Frey T.G., Chan D.C. Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol. Biol. Cell. 2009, 20:3525-3532.
49. Viladomiu M., Hontecillas R., Lu P., Bassaganya-Riera J. Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evid. Based Complement. Altern. Med. 2013, 10.1155/2013/789764.
50. Wang J., Green P.S., Simpkins J.W. Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. J. Neurochem. 2001, 77:804-811.
51. Wilson-Fritch L., Burkart A., Bell G., Mendelson K., Leszyk J., Nicoloro S., et al. Mitochondrial biogenesis and remodelling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol. Cell. Biol. 2003, 23:1085-1104.
52. Wu S., Zhou F., Zhang Z., Xing D. Mitochondrial oxidative stress causes mitochondrial fragmentation via differential modulation of mitochondrial fission-fusion proteins. FEBS J. 2011, 278:941-954.
53. Yan J., Zhao Y., Suo S., Liu Y., Zhao B. Green tea catechins ameliorate adipose insulin resistance by improving oxidative stress. Free Radic. Biol. Med. 2012, 52:1648-1657.
54. Yu T., Sheu S.S., Robotham J.L., Yoon Y. Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. Cardiovasc. Res. 2008, 79:341-351.
55. Zolezzi J.M., Silva-Alvarez C., Ordenes D., Godoy J.A., Carvajal F.J., Santos M.J., et al. Peroxisome proliferator-activated receptor (PPAR) gamma and PPARalpha agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders?. PLoS One 2013, 10.1371/journal.pone.0064019.